Incidence Rate of 5-Fluorouracil-Induced Hyperpigmentation
The incidence of hyperpigmentation from systemic 5-fluorouracil therapy ranges from 2-5% based on the most recent evidence, though this represents a rare but recognized dermatological toxicity 1.
Evidence Quality and Context
The available evidence on systemic 5-FU hyperpigmentation incidence is limited. The 2-5% incidence figure comes from a 2022 case report discussing serpentine supra-venous hyperpigmentation (SSH), a specific pattern of pigmentation following intravenous 5-FU administration 1. This represents the most direct data available for systemic therapy.
A 2026 systematic review and meta-analysis examining drug-induced hyperpigmentation across multiple medication classes found an overall pooled incidence of 36.7% for DIH from all causes, with antineoplastic agents showing a 35.5% incidence 2. However, this broader category includes multiple chemotherapeutic agents beyond 5-FU alone, making it less specific for answering your question.
Topical vs. Systemic Considerations
It's critical to distinguish between topical and systemic 5-FU administration:
Topical 5-FU (used for actinic keratoses, warts, and Bowen's disease) causes hyperpigmentation when used for "longer periods" according to British Association of Dermatologists guidelines 3. The guidelines note this occurs "or less frequently hypopigmentation" but provide no specific incidence rates.
Systemic 5-FU absorption from topical application is minimal (approximately 5-6 mg per 100 mg daily dose, or 0.76% of applied dose) 4, which explains why systemic toxicities from topical use are uncommon.
Clinical Patterns of 5-FU Hyperpigmentation
When hyperpigmentation occurs with systemic 5-FU, several distinct patterns have been documented 1:
- Serpentine supra-venous hyperpigmentation (SSH): Pigmentation following the pattern of superficial veins used for infusion
- Diffuse hyperpigmentation: Affecting face and palms
- Macular pigmentary changes: Particularly on palms and soles
Important Caveats
The 2-5% incidence should be interpreted cautiously because:
- Most published literature focuses on topical 5-FU for dermatological conditions rather than systemic chemotherapy
- Hyperpigmentation may be underreported as it doesn't typically affect morbidity or mortality
- The incidence may vary based on cumulative dose, infusion technique, and patient skin type
- Recent animal studies suggest sex differences may exist in 5-FU-induced pigmentation, with males showing greater susceptibility 5
For systemic 5-FU chemotherapy, counsel patients that hyperpigmentation occurs in approximately 2-5% of cases, typically manifesting as darkening along venous pathways or in sun-exposed areas. This is generally a cosmetic concern rather than a serious toxicity, though it can impact quality of life, particularly in female patients 5.